Poststroke depression

Topics in Stroke Rehabilitation

Volumn 15, Issue 1, 2008, Pages 13-21

  Dafer, Rima M ^a   Rao, Murali ^a   Shareef, Aisha ^a   Sharma, Aparna ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Depression; Outcome; Stroke

Indexed keywords

ALPHA TOCOPHEROL; AMPHETAMINE; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; FLUOXETINE; MEMANTINE; METHYLPHENIDATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NIMODIPINE; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL FEATURE; COGNITIVE DEFECT; CONVALESCENCE; DEPRESSION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FAMILY LIFE; FUNCTIONAL DISEASE; HUMAN; MORTALITY; NEUROPSYCHOLOGY; PATHOPHYSIOLOGY; POST STROKE SYNDROME; PREVALENCE; PSEUDOBULBAR PALSY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIAL BEHAVIOR; STROKE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AGED; DEPRESSIVE DISORDER; DIAGNOSIS, DIFFERENTIAL; HUMANS; PSYCHIATRIC STATUS RATING SCALES; STROKE; TREATMENT OUTCOME;

EID: 38549109617     PISSN: 10749357     EISSN: None     Source Type: Journal    
DOI: 10.1310/tsr1501-13     Document Type: Review

References (67)

1. Kaplan A. Neuropsychiatric symptoms in post-stroke patients. Psychiatric Times. 2005;22.
2. Whyte EM, Mulsant BH, Vanderbilt J, Dodge HH, Ganguli M. Depression after stroke: a prospective epidemiological study. J Am Geriatr Soc. 2004;52(5):774-778.
3. Ramasubbu R, Robinson RG, Flint AJ, Kosier T, Price TR. Functional impairment associated with acute poststroke depression: the Stroke Data Bank Study. J Neuropsychiatry Clin Neurosci. 1998;10(1):26-33.
4. Whyte EM, Mulsant BH. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry. 2002;52(3):253-264.
5. Astrom M, Adolfsson R, Asplund K. Major depression in stroke patients. A 3-year longitudinal study. Stroke. 1993;24(7):976-982.
6. Everson SA, Roberts RE, Goldberg DE, Kaplan GA. Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med. 1998;158(10):1133-1138.
7. Robinson RG, Bolduc PL, Price TR. Two-year longitudinal study of poststroke mood disorders: diagnosis and outcome at one and two years. Stroke. 1987;18(5):837-843.
8. Simonsick EM, Wallace RB, Blazer DG, Berkman LF. Depressive symptomatology and hypertension-associated morbidity and mortality in older adults. Psychosom Med. 1995;57(5):427-435.
9. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M. Clinically defined vascular depression. Am J Psychiatry. 1997;154(4):562-565.
10. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. "Vascular depression" hypothesis. Arch Gen Psychiatry. 1997;54(10):915-922.
11. Pohjasvaara T, Vataja R, Leppavuori A, Kaste M, Erkinjuntti T. Depression is an independent predictor of poor long-term functional outcome poststroke. Eur J Neurol. 2001;8(4):315-319.
12. Singh A, Black SE, Herrmann N, et al. Functional and neuroanatomic correlations in poststroke depression: the Sunnybrook Stroke Study. Stroke. 2000;31(3):637-644.
13. Kotila M, Numminen H, Waltimo O, Kaste M. Depression after stroke: results of the FINNSTROKE Study. Stroke. 1998;29(2):368-372.
14. Berg A, Palomaki H, Lehtihalmes M, Lonnqvist J, Kaste M. Poststroke depression: an 18-month follow-up. Stroke. 2003;34(1):138-143.
15. Mast BT. Cerebrovascular disease and late-life depression: a latent-variable analysis of depressive symptoms after stroke. Am J Geriatr Psychiatry. 2004;12(3):315-322.
16. Paolucci S, Gandolfo C, Provinciali L, Torta R, Toso V. The Italian multicenter observational study on poststroke depression (DESTRO). J Neurol. 2006;253(5):556-562.
17. Larson SL, Owens PL, Ford D, Eaton W. Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke. 2001;32(9):1979-1983.
18. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M. Clinical determinants of poststroke dementia. Stroke. 1998;29(1):75-81.
19. Schubert DS, Burns R, Paras W, Sioson E. Increase of medical hospital length of stay by depression in stroke and amputation patients: a pilot study. Psychother Psychosom. 1992;57(1-2):61-66.
20. Jonas BS, Mussolino ME. Symptoms of depression as a prospective risk factor for stroke. Psychosom Med. 2000;62(4):463-471.
21. Ohira T, Iso H, Satoh S, et al. Prospective study of depressive symptoms and risk of stroke among Japanese. Stroke. 2001;32(4):903-908.
22. Robinson RG, Starr LB, Price TR. A two year longitudinal study of mood disorders following stroke. Prevalence and duration at six months follow-up. Br J Psychiatry. 1984;144:256-262.
23. Robinson RG, Starkstein SE, Price TR. Post-stroke depression and lesion location. Stroke. 1988;19(1):125-126.
24. Starkstein SE, Cohen BS, Fedoroff P, Parikh RM, Price TR, Robinson RG. Relationship between anxiety disorders and depressive disorders in patients with cerebrovascular injury. Arch Gen Psychiatry. 1990;47(3):246-251.
25. Starkstein SE, Robinson RG, Berthier ML, Parikh RM, Price TR. Differential mood changes following basal ganglia vs thalamic lesions. Arch Neurol. 1988;45(7):725-730.
26. Starkstein SE, Robinson RG, Price TR. Comparison of cortical and subcortical lesions in the production of poststroke mood disorders. Brain. 1987;110(Pt 4):1045-1059.
27. Robinson RG, Kubos KL, Starr LB, Rao K, Price TR. Mood changes in stroke patients: relationship to lesion location. Compr Psychiatry. 1983;24(6):555-566.
28. Bhogal SK, Teasell R, Foley N, Speechley M. Lesion location and poststroke depression: systematic review of the methodological limitations in the literature. Stroke. 2004;35(3):794-802.
29. Carson AJ, MacHale S, Allen K, et al. Depression after stroke and lesion location: a systematic review. Lancet. 2000;356(9224):122-126.
30. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry. 2000;57(11):1071-1076.
31. Sachdev PS, Chen X, Joscelyne A, Wen W, Brodaty H. Amygdala in stroke/transient ischemic attack patients and its relationship to cognitive impairment and psychopathology: the Sydney Stroke Study. Am J Geriatr Psychiatry. 2007;15(6):487-496.
32. Brodaty H, Withall A, Altendorf A, Sachdev PS. Rates of depression at 3 and 15 months poststroke and their relationship with cognitive decline: the Sydney Stroke Study. Am J Geriatr Psychiatry. 2007;15(6):477-486.
33. Fujikawa T, Yamawaki S, Touhouda Y. Incidence of silent cerebral infarction in patients with major depression. Stroke. 1993;24(11):1631-1634.
34. Heresco-Levy U, Javitt DC. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol. 1998;8(2):141-152.
35. Glodzik-Sobanska L, Slowik A, McHugh P, et al. Single voxel proton magnetic resonance spectroscopy in post-stroke depression. Psychiatry Res. 2006;148(2-3):111-120.
36. Hickie I, Scott E. Late-onset depressive disorders: a preventable variant of cerebrovascular disease? Psychol Med. 1998;28(5):1007-1013.
37. Aben I, Verhey F, Strik J, Lousberg R, Lodder J, Honig A. A comparative study into the one year cumulative incidence of depression after stroke and myocardial infarction. J Neurol Neurosurg Psychiatry. 2003;74(5):581-585.
38. Lyness JM. The cerebrovascular model of depression in late life. CNS Spectr. 2002;7(10):712-715.
39. Lyness JM, Caine ED, King DA, Conwell Y, Cox C, Duberstein PR. Cerebrovascular risk factors and depression in older primary care patients: testing a vascular brain disease model of depression. Am J Geriatr Psychiatry. 1999;7(3):252-258.
40. Steffens DC, Krishnan KR, Crump C, Burke GL. Cerebrovascular disease and evolution of depressive symptoms in the cardiovascular health study. Stroke. 2002;33(6):1636-1644.
41. Holley C, Murrell SA, Mast BT. Psychosocial and vascular risk factors for depression in the elderly. Am J Geriatr Psychiatry. 2006;14(1):84-90.
42. Kang Y. Effect of uncertainty on depression in patients with newly diagnosed atrial fibrillation. Prog Cardiovasc Nurs. 2006;21(2):83-88.
43. Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety and quality of life in patients with atrial fibrillation [Electronic version]. Chest. 2007;132:1259-1264.
44. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry. 2006;63(3):273-279.
45. Verdelho A, Henon H, Lebert F, Pasquier F, Leys D. Depressive symptoms after stroke and relationship with dementia: a three-year follow-up study. Neurology. 2004;62(6):905-911.
46. Aben I, Denollet J, Lousberg R, Verhey F, Wojciechowski F, Honig A. Personality and vulnerability to depression in stroke patients: a 1-year prospective follow-up study. Stroke. 2002;33(10): 2391-2395.
47. Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry. 2003;160(10):1823-1829.
48. Herrmann N, Black SE, Lawrence J, Szekely C, Szalai JP. The Sunnybrook Stroke Study: a prospective study of depressive symptoms and functional outcome. Stroke. 1998;29(3):618-624.
49. Angelelli P, Paolucci S, Bivona U, et al. Development of neuropsychiatric symptoms in poststroke patients: a cross-sectional study. Acta Psychiatr Scand. 2004;110(1):55-63.
50. Reynolds CF 3rd, Lebowitz BD, Schneider LS. The NIH Consensus Development Conference on the Diagnosis and Treatment of Depression in Late Life: an overview. Psychopharmacol Bull. 1993;29(1):83-85.
51. Spiller JA, Keen JC. Hypoactive delirium: assessing the extent of the problem for inpatient specialist palliative care. Palliat Med. 2006;20(1):17-23.
52. van de Weg FB, Kuik DJ, Lankhorst GJ. Post-stroke depression and functional outcome: a cohort study investigating the influence of depression on functional recovery from stroke. Clin Rehabil. 1999;13(3):268-272.
53. Morris PL, Robinson RG, Samuels J. Depression, introversion and mortality following stroke. Aust N Z J Psychiatry. 1993;27(3):443-449.
54. Bourgeois JA, Hilty DM, Chang CH, Wineinger MA, Servis ME. Poststroke neuropsychiatric illness: an integrated approach to diagnosis and management. Curr Treat Options Neurol. 2004;6(5):403-420.
55. Narushima K, Kosier JT, Robinson RG. Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. J Nerv Ment Dis. 2002;190(5):296-303.
56. Robinson RG. Neuropsychiatric consequences of stroke. Annu Rev Med. 1997;48:217-229.
57. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet. 1984;1(8372):297-300.
58. Andersen G, Vestergaard K, Lauritzen LU. [Effective treatment of depression following apoplexy with Citalopram]. Ugeskr Laeger. 1995;157(14):2000-2003.
59. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke. 2000;31(8):1829-1832.
60. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157(3):351-359.
61. Johnson ML, Roberts MD, Ross AR, Witten CM. Methylphenidate in stroke patients with depression. Am J Phys Med Rehabil. 1992;71(4):239-241.
62. Taragano FE, Allegri R, Vicario A, Bagnatti P, Lyketsos CG. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of "vascular depression." Int J Geriatr Psychiatry. 2001;16(3):254-260.
63. Kales HC, Maixner DF, Mellow AM. Cerebrovascular disease and late-life depression. Am J Geriatr Psychiatry. 2005;13(2):88-98.
64. Matsuura E, Ohta A, Kanegae F, et al. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol. 2003;30(8):1782-1787.
65. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001;40(9):1038-1043.
66. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry. 2004;65(12):1642- 1653.
67. Serebruany VL, Glassman AH, Malinin AI, et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail. 2003;5(4):517-521.